These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1418 related items for PubMed ID: 11062945

  • 1. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 2. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [Abstract] [Full Text] [Related]

  • 4. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 5. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE, Phillips GL.
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [Abstract] [Full Text] [Related]

  • 8. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K, Utsumi M, Shimoyama M.
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [Abstract] [Full Text] [Related]

  • 9. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM.
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [Abstract] [Full Text] [Related]

  • 10. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F.
    Haematologica; 1993 Jun; 78(4):230-5. PubMed ID: 7507457
    [Abstract] [Full Text] [Related]

  • 11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 12. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
    Carella AM, Carlier P, Congiu A, Occhini D, Nati S, Santini G, Pierluigi D, Giordano D, Bacigalupo A, Damasio E.
    Bone Marrow Transplant; 1991 Aug 15; 8(2):99-103. PubMed ID: 1718517
    [Abstract] [Full Text] [Related]

  • 13. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S, Geara F, Nabbout B, Farah RA, Shabb NS, Hajjar T, Khogali M.
    Radiat Oncol Investig; 1999 Aug 15; 7(6):365-73. PubMed ID: 10644060
    [Abstract] [Full Text] [Related]

  • 14. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
    Bone Marrow Transplant; 1997 Sep 15; 20(6):451-8. PubMed ID: 9313877
    [Abstract] [Full Text] [Related]

  • 15. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I, Ganser D, Freitag EM, Bohndorf W.
    Strahlenther Onkol; 1994 Sep 15; 170(9):516-23. PubMed ID: 7524173
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):765-81. PubMed ID: 15183480
    [Abstract] [Full Text] [Related]

  • 17. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J.
    Biol Blood Marrow Transplant; 1997 Jun 01; 3(2):98-106. PubMed ID: 9267670
    [Abstract] [Full Text] [Related]

  • 18. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
    Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, Bökkerink JP, Riepenhausen M, Lüders H, Pötter R, Rühl U, DAL/GPOH.
    J Clin Oncol; 2005 Sep 01; 23(25):6181-9. PubMed ID: 16135485
    [Abstract] [Full Text] [Related]

  • 19. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A.
    J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410
    [Abstract] [Full Text] [Related]

  • 20. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F.
    Haematologica; 1999 Oct 01; 84(10):917-23. PubMed ID: 10509040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.